Background: The dose intensity of chemotherapy for patients with ovarian carcinoma remains a controversial issue. Few randomised trials have been conducted examining dose intensity using the same total dose of chemotherapy. This study was designed to investigate two schedules of chemotherapy using standard and higher dose intensity with both groups receiving the same total dose.
Introduction
Ovarian carcinoma is the seventh most common cancer of women in the world with approximately 140,000 new cases diagnosed each year. The disease is responsible for the greatest number of deaths from gynaecological malignancy in Europe and North America [1] . Cisplatin-based combination chemotherapy has been attended by an improvement in clinical response rates and progression-free survival compared with therapy using an alkylating agent alone or combinations without cisplatin [2] [3] [4] . However, improvements in overall survival have been modest. In 1991 a meta-analysis of 45 randomised clinical trials of chemotherapy was carried out [5] . This analysis suggested that in terms of survival, immediate platinum-based treatment was better than non-platinum regimens, platinum in combination was better than single agent platinum when used in the same dose, and cisplatin and carboplatin were equally effective. A further meta-analysis by the Ovarian Cancer Meta-Analysis Project [6] analysing four randomised clinical trials comparing cyclophosphamide and cisplatin with cyclophosphamide doxorubicin and cisplatin (CAP) showed a significant survival benefit for the doxorubicin-containing combinations. However, the dose intensity of CAP was greater than the control arm in three of the trials and it remained unresolved to what extent the benefit of CAP was from the greater dose intensity or the contribution of doxorubicin itself.
The suggested survival advantage attended by the introduction of additional drugs to chemotherapy involving only a platinum drug was small and an alternative approach with assessment of the role of dose intensity using randomised trials has been used at the Christie Cancer Centre since 1987. The major obstacle to improvement in overall survival is the development of drug resistance. Although several methods have been suggested to overcome this, a substantial increase in the dose intensity of chemotherapy may overcome resistance mediated by many of the mechanisms of resistance. A steep dose-response curve has been demonstrated in vitro for ovarian carcinoma [7] and a retrospective analysis of published clinical trials by Levine and Hryniuk [8] has suggested that objective tumour response rates are increased with regimens associated with a greater dose intensity. The number of prospective randomised clinical trials testing this relationship is, however, limited, [9] [10] [11] [12] [13] [14] and the role of dose intensive chemotherapy remains controversial. The issues involved have been reviewed by our group [15] .
The results of a randomised dose intensity study carried out at the Christie Cancer Centre in patients with ovarian carcinoma comparing our 'standard' full dose alternating, combined chemotherapy given at fourweekly intervals for six cycles with half dose chemotherapy given using the same schedule and total dose over 12 cycles has been published [12] . The study was terminated prematurely when 99 patients were entered because the clinical response rate was lower and significantly more patients had progression during treatment on the low dose intensity arm although the eventual overall survival was not significantly different The study reported here compares the same 'standard' full dose alternating chemotherapy given at four-weekly intervals with the more intensive schedule given threeweekly in an attempt to improve the clinical response rate, progression-free survival and overall survival. doxorubicin (50 mg/m 2 ). A total of six cycles of treatment was planned, and patients were randomised to receive cycles at threeweekly or four-weekly intervals.
Carboplatin was administered in one litre of 5% dextrose over one hour, immediately followed by cyclophosphamide in one litre of normal saline infused over one hour. The dose of carboplatin was calculated in mg/m 2 based on the patient's body surface area, provided the creatinine clearance was above 50 ml/min. The glomerular filtration rate was calculated using the Cockroft formula [16] for each patient treated, from which the AUC of carboplatin dosage could be deduced using Calverfs formula [17] . This exercise was carried out retrospectively to compare the planned AUC of carboplatin with the actual dose administered based on body surface area.
Doxorubicin was administered as a slow intravenous injection into a fast running infusion of normal saline. Ifosfamide was administered in one litre of normal saline containing 5 g/m 2 of mesna over eight hours, followed by a further two litres of normal saline containing 6 g/m 2 of mesna given over eight hours. Anu'emeu'c therapy was in the form of intravenous high dose maxolon (100 mg) or ondansetron with the addition of dexamethasone (8 mg) when vomiting was severe.
If at the time of planned chemotherapy there was evidence of myelosuppression (WBC <3.0 x lO'/l) or declining renal function (creatinine clearance <50 ml/min), treatment was delayed by one week, or until the above parameters had recovered. Dose modifications were made in accordance with the nadir count of the preceding cycle of treatment Only carboplatin and doxorubicin were dose reduced. If, for any reason, treatment was delayed for three weeks or more, the patient was taken off study.
Patients and methods
Ninety-seven patients with epithelial ovarian cancer, FIGO stage Ic-IV were entered into the more dose-intensive arm (three-weekly treatment), and 47 patients into the standard arm (four-weekly treatment), between 1989 and 1994 using a 2:1 randomisation. A 2:1 randomisation was used since considerable experience was already available for the four-weekly schedule from our previous randomised study. At randomisation patients were stratified according to histologica] grade and amount of post-operative residual tumour (greater or less than 2 cm). The two arms of the study were well balanced in terms of the major prognostic features.
Patients were considered eligible for the study if they had FIGO stage II-IV ovarian carcinoma, or high risk stage I disease (defined as (a) ruptured cyst, (b) involved ascites, (c) high grade tumour). The pathology of all the ovarian tumours was reviewed by an experienced pathologist (HB) prior to entry into the study, and the following histological types were acceptable: serous, mucinous or endometrioid adenocarcinoma, clear cell (mesonephroid) carcinoma and undifferentiated carcinoma of the ovary. Other eligibility criteria included age <65 years, Karnofsky performance >60%, a life-expectancy greater than three months and no previous recorded history of malignancy or treatment with chemotherapy or radiotherapy. Patients who were a poor medical risk because of non-malignant systemic disease were not eligible. It was specified before treatment that the leucocyte count should be >3.5 x 10 9 /l, platelet count > 150 x lO'/l, serum creatinine <0.12 mmol/1 and creatinine clearance > 50 ml/minute. Before entry all patients were required to give informed consent At entry all patients had a history taken and underwent physical examination. The extent of disease was assessed by a chest radiograph and computed tomographic scan (CT) of the abdomen and pelvis.
Chemotherapy
All patients received alternating cycles of carboplatin (300 mg/m /week using the method described by Hryniuk [18] . The total cumulative dose (mg/m 2 ) and the dose intensity were calculated for each individual patient and for each drug received. The received dose intensity was calculated after three cycles, and after six cycles of treatment, by dividing the cumulative dose received (mg/m 2 ) by the number of weeks taken to administer the specified number of cycles. One dose interval was added to the treatment period to adjust for methodological problems in dealing with those patients receiving less than the specified number of cycles [19] . The relative dose intensity was calculated by dividing the received dose intensity for that drug by the planned dose intensity for the same drug. A value of 1.0 indicated that the patient had received 100% of the planned dose intensity.
Tumour response and patient follow-up
The criteria used for response to treatment were according to those denned by the World Health Organisation [20] , and were determined by pelvic and abdominal examination, and abdomino-pelvic CT scan before and after chemotherapy. The pre-and post-chemotherapy scans were reviewed by two radiologists (CC and MD). Patients who had no residual disease seen on the pretreatment CT scan nor on the CT scan performed post-chemotherapy were not included in the evaluation of response unless a second-look laparotomy was undertaken confirming transition from residual disease to pathological complete remission. All patients were included in the analysis of progression-free and overall survival. Second-look laparotomy was not obligatory, but was recommended when initial surgery was incomplete.
Patients were followed-up after chemotherapy three monthly for two years and six monthly thereafter. Patients with symptomatic, relapsed disease were treated with melphalan, or with single agent carboplatin if more than one year had elapsed since completing their initial therapy.
Statistical methods
The study was planned to include 150 patients to identify a significant difference of 20% at the 5% significance level using a one-tailed test With an equal randomisation the power is 80% and is only reduced to 77% if a 2:1 randomisation is used [21] . Overall and progression-free survival were measured from the date of treatment. All eligible patients were included, and all causes of death were used to calculate survival by Kaplan-Meier [22] estimates. The balance of prognostic variables was evaluated by the Chi-square test on contingency tables for categorical variables and by the Mann-Whitney U-test if the prognostic variable was measured on a continuous scale. Survival and progression-free survival were displayed using Kaplan-Meier survival plots and were compared by the log rank test Multivariate analysis was by the Cox proportional hazards method. Comparisons of haematological toxicities and response rates were made using the Chi-square test for contingency tables.
Results
ysis confirmed that the following parameters were highly significant prognostic variables in terms of overall survival: FIGO stage, post-operative residual disease status, histological grade of tumour, Karnofsky performance status at start of treatment and prechemotherapy serum CA125 level (Table 2) . A Cox multivariate analysis identified advanced FIGO stage (P = 0.019) and a high prechemotherapy serum CA125 level (P-0.0006) as independent factors adversely influencing survival ( Table 2) .
The planned dose intensification in the three-weekly arm relative to the standard four-weekly treatment arm was 1.3. Patients in both treatment arms received a similar relative cumulative dose of each drug in the regimen ( Table 3 ). The relative cumulative dose was calculated by dividing the actual total dose of drug received (mg/m 2 ) by the planned cumulative dose of drug (mg/m 2 ). A value of 1.0 indicated that a patient had received 100% of the planned cumulative dose of drug.
The relative dose intensity of individual drugs was calculated for each patient, after three and six cycles of treatment. Table 4 shows the percent of patient in each treatment arm receiving <70%, 70% < 80%, 80% < 90% and > 90% of the planned dose intensity of each drug. After three treatment cycles 64% (60/93) of patients in the three-weekly arm received >90% of the planned dose intensity of each drug, whereas 83% of patients in the four-weekly arm received >90%. Fewer patients in each trial arm completed all six cycles of treatment, but of those who did, 65% undergoing three-weekly chemotherapy and 76% in the fourweekly arm received >90% of the planned dose intensity.
Tumour response and survival
Patients who had no initial measurable disease, and did not progress on treatment or undergo second-look laparotomy were considered unevaluable for response. There were 19 (19%) unevaluable patients in the threeweekly arm and eight (17%) in the four-weekly arm. The combined overall response rate (complete and partial response) in the 114 assessable patients was 65.7%. The combined response rate for the threeweekly arm was 66.7% and for the four-weekly arm 64%. The proportion of patients showing static or progressive disease during treatment was 33.3% and 36%, respectively.
When the two treatment arms were compared in terms of overall survival and progression-free survival, no significant advantage was seen for patients in the more dose-intensive group (Figure la and b) . The median overall survival in the three-weekly treatment arm was 730 days, and 740 days in the four-weekly arm. The median progression-free survival was 500 days and 483 days in the three-and four-weekly arms, respectively.
Toxicity
Progressive disease resulted in eight (8%) patients in the three-weekly arm and six (13%) in the four-weekly arm being withdrawn from treatment before the completion of six cycles of therapy. This difference was not statistically significant. Seven patients (7%) in the threeweekly arm and one (2%) in the four-weekly arm were withdrawn due to prolonged neutropenia. In the dose intensive (three-weekly) arm one patient failed to complete treatment due to intermittent disease, one due to an allergic reaction and one due to patient refusal. One patient was later found to be a protocol violation due to misidentification of the histology. In the four-weekly treatment arm one patient failed to complete treatment for each of the following reasons: severe infection, intercurrent disease, renal failure and patient refusal, and two due to intolerance of side-effects (nausea and vomiting). Overall, 34 of 47 patients (72%) in the fourweekly arm and 78 of 97 patients (80%) in the threeweekly arm, completed six cycles of chemotherapy. However, 46 (8.5%) of these treatments were delayed by one or more weeks in the three-weekly arm, compared with only 11 (4.6%) in the four-weekly arm. The most common cause for delay in treatment was prolonged neutropenia, accounting for 30 delays (5.6%) in the three-weekly arm and nine delays (3.8%) in the four-weekly arm (Table 5 ). Of the patients who experienced treatment delays, all except one were delayed in two treatment cycles. Overall, there were 23 patients (27%) in the three-weekly arm and six (13%) in the four-weekly arm in whom treatment was delayed.
CTC grade 2 or 3 non-haematological toxicities such as nausea and vomiting, alopecia, bowel disturbance and peripheral neuropathy, affected the same proportion of patients in each treatment arm. Haematological toxicity, however, was more marked in patients treated at three-weekly intervals. Red blood cell transfusions were administered to patients in 9% of treatment cycles in the three-weekly arm (47 occa- sions) and 5% of treatment cycles (12 occasions) in the four-weekly arm. Although neutropenia was the cause of delay in the treatment schedule in 5.6% and 3.8% of cases in the three-and four-weekly arms, respectively, the proportion of patients with recorded infections requiring intravenous or oral antibiotic therapy was the same in each treatment arm (see Table 6 ). Figure 2 (8) 76 (78) 75 (77) 14 (14) 1 ( ing regimens in each arm. Carboplatin and cyclophosphamide (cycles 1,3 and 5) had a more profound effect on platelet count (Figure 2a) , whereas doxorubicin and infosfamide (cycles 2, 4 and 6) had their greatest myelosuppressive effect on white blood cell count (Figure 2b ). There were no significant differences in the nadir counts of white blood cells, platelets or in the level of haemoglobin between the two arms.
Discussion
Our study investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma using a four drug combination in patients with FIGO stage Ic-TV disease did not show any significant difference in response rate, progression-free survival or overall survival between the two treatment arms. The combined response rate (complete and partial response) was 64% in the standard therapy arm and 66.7% in the more intensive arm. The median overall survival in the standard and more dose intensive arms was 740 and 730 days, respectively, with a three-year survival of approximately 40% for both groups. The median progressionfree survival was 483 days in the 'standard' and 500 days in the more dose-intensive arm. It was planned that patients in both treatment arms should receive the same total dose of each drug with dose intensity being the only variable. Calculation of the relative cumulative dose of each drug for all patients confirmed that this had been achieved. Patients in the higher dose arm should have received 1.3 times the standard dose therapy, however, the results of the study showed that >90% of the planned dose intensity was achieved in only 65% of patients.
The most common cause for delay in treatment or dose reduction was neutropenia. Thrombocytopenia alone was rarely a cause for alteration of the treatment schedule. Non-haematological toxicities such as renal impairment, ototoxicity and peripheral neuropathy, which are known to be dose limiting in dose intensive chemotherapy using cisplatin were uncommon in this study.
There have been a number of prospective randomised trials addressing the issue of dose-intensity in the management of patients with ovarian cancer [9] [10] [11] 13, 14] . Inspite of this, no firm conclusions have been reached and the role of dose-intensification remains controversial. In these trials the relative dose intensity between the arms of 1.6-2.0 was not associated with any differences in response rate, progression-free interval or overall survival. The report by Bella et al. [14] described a trend for increased survival at four years (31% vs. 13%) in favour of the more intensive treatment but this difference was not statistically significant. A further randomised trial reported by our group comparing 'standard' dose-intensive chemotherapy with the same chemotherapy delivered at half dose intensity but the same total dose was associated with a reduced response rate and progTession-free survival for the less intensive therapy but overall survival was not significantly different [12] . The further increase in dose intensity using the same drugs evaluated in the present study has shown no added advantage over our 'standard' four-weekly therapy. This was the case both for the present study and a retrospective comparison with the 'standard' arm of our first dose intensity trial.
In two randomised trials both dose intensity and the total dose of drug was varied and an overall survival advantage for the higher dose arms was reported in both studies [9, 11] . However, the trial from Hong Kong [9] included only 28 evaluable patients.
There has been a suggestion that higher dose intensive therapy may be more effective when debulking surgery is optimal and the amount of residual disease small [23] . However, we have shown no advantage to the higher dose intensity in either optimally debulked patients (<2 cm residual disease) or in sub-optimally debulked patients (> 2 cm). These features were stratified for randomisation in our study and the two treatment arms were well matched.
It is difficult to draw any firm conclusions from published work regarding the relationship between clinical outcome and the intensity of chemotherapy delivered in epithelial ovarian cancer. However, most of the available data concerns randomised trials where the difference between the arms in terms of dose intensity was relatively modest. The chemotherapy used in reported randomised trials examined a less than two fold difference in planned intensity and no trial involved therapy of sufficient intensity to warrant haemopoietic growth factor or peripheral blood progenitor cell support. It has been suggested that if the true benefit of dose intensive therapy lies in its ability to overcome relative drug resistance, then a greater than 5-fold increase in dose would be desirable [24] . In our study this would not have been possible due to the dose-limiting effect of myelosuppression. At the modest dose intensification administered in this study, only 65% of patients actually received >90% of the planned higher dose.
In order to further assess the role of dose intensity in the management of patients with ovarian carcinoma, more dose-intensive schedules of chemotherapy need to be evaluated. In order for this therapy to be administered safely, haematopoietic support with growth factors and/or autotransfusions of blood progenitor cells is required. The problems of non-haematological toxic-ity following these more intensive regimens also needs addressing. A recently published study by the Gynaecology Oncology Group in the USA has shown that incorporating paclitaxel into first line therapy improves the duration of progression-free survival and overall survival in women with incompletely resected stage HI and stage IV ovarian cancer [25] . Dose-intensive therapy incorporating paclitaxel in the regimen deserves attention although neuropathy and not myelotoxicity may be dose-limiting in these patients [26] .
